Recent developments highlight LivaNova's Q3 2026 financial results, operational updates, and market activity.

• LivaNova reported Q3 2026 results with net income of $34.3 million and raised full-year 2026 revenue and adjusted diluted EPS guidance [N4].
• The company surpassed Q3 2026 earnings and revenue expectations, reflecting operational progress [N5].
• The Q3 2026 earnings call transcript provides detailed insights into performance and strategic initiatives [N2].
• Healthcare stocks including LivaNova showed positive market movement in early November 2026 [N1].

LivaNova's revenue growth across all segments and regions, combined with improved segment income and cost efficiencies, demonstrates operational strength. The company's investment in R&D, particularly in neuromodulation therapies like the aura6000 System, indicates a commitment to innovation. Recent quarterly results show positive financial performance and raised guidance, reflecting management's execution capabilities. Effective liquidity management and ongoing ERP system upgrades support operational resilience. The company's ability to manage and reduce litigation and restructuring expenses further supports its financial health.

LivaNova faces risks from legal and environmental liabilities, including the significant SNIA environmental expense recorded in 2025. The company operates in a highly regulated industry with exposure to reimbursement and regulatory changes that could impact product adoption and profitability. R&D investments carry execution risk and may not yield commercial success. Currency fluctuations and geopolitical factors could affect international revenue. The ongoing ERP system implementation may pose operational challenges. Additionally, competitive pressures in medical technology require sustained innovation and cost management to maintain margins.

LivaNova's moat is supported by its diversified product portfolio in specialized medical technology segments, including Cardiopulmonary and Neuromodulation. The company benefits from established customer relationships with hospitals and surgeons globally, proprietary technologies such as the Essenz Perfusion System, and ongoing investment in R&D for innovative therapies like the aura6000 System. Its geographic diversification across major markets reduces dependency on any single region. The company's ability to manage regulatory and litigation risks, including environmental liabilities, also contributes to its competitive positioning. However, the medical technology industry is competitive and subject to regulatory scrutiny, which requires continuous innovation and compliance.

• Legal and Environmental Liabilities: LivaNova recorded a substantial SNIA environmental liability expense following an Italian Supreme Court ruling, representing a material contingent liability. Ongoing litigation related to the 3T Heater-Cooler device also poses financial risk.
• Regulatory and Reimbursement Risks: The company operates in multiple jurisdictions with varying regulatory requirements and reimbursement environments, which may affect product approvals, market access, and pricing.
• R&D Execution Risk: Investments in product development, such as the aura6000 System for OSA, involve uncertainties regarding clinical success, regulatory approval, and market acceptance.
• Operational Risks from ERP Implementation: The multi-year global ERP system upgrade to SAP S/4HANA involves changes to internal controls and processes, which could impact financial reporting and operational efficiency if not managed effectively.
• Market and Competitive Risks: LivaNova faces competition from other medical technology companies, requiring continuous innovation and cost control to maintain market share and profitability.

• LivaNova PLC operates primarily in two segments: Cardiopulmonary and Neuromodulation, with detailed revenue and segment income disclosed in the 2025 annual report [S1].
• In 2025, LivaNova reported net revenue of $1.388 billion, a 10.7% increase from 2024, with growth across all geographic regions including the United States, Europe, and Rest of World [S1].
• Cardiopulmonary segment revenue was $785.4 million in 2025, up 14.9% year-over-year, driven by consumables demand and Essenz Perfusion System sales [S1].
• Neuromodulation segment revenue was $592.8 million in 2025, up 7.0% year-over-year, with growth across all regions [S1].
• Segment income increased in both segments in 2025, with Cardiopulmonary income at $108.3 million and Neuromodulation at $215.5 million, reflecting revenue growth and changes in R&D expenses [S1].
• Cost of sales was 32.3% of net revenue in 2025, slightly higher than 2024, due to product mix changes [S1].
• Selling, general, and administrative expenses were 39.5% of net revenue in 2025, a decrease from 2024, attributed to favorable fixed cost leverage [S1].
• Research and development expenses were 13.4% of net revenue in 2025, down from 14.6% in 2024, reflecting reduced costs in the DTD program partially offset by increased spending on the aura6000 System for OSA treatment [S1].
• Other operating expenses decreased significantly in 2025, mainly due to lower litigation provisions related to the 3T Heater-Cooler device and reduced restructuring expenses [S1].
• LivaNova recorded a significant SNIA environmental liability expense in 2025 following an Italian Supreme Court decision holding the company liable for environmental liabilities related to a demerged company [S1].
• Interest expense decreased in 2025 compared to 2024, due to early debt repayments and lower interest rates [S1].
• The company reported net income of $34.3 million for Q3 2026 and basic EPS of $0.62 as of September 30, 2026 [S2].
• Liquidity ratios as of September 30, 2026, include a current ratio of 1.46 and a cash ratio of 0.76, with cash and equivalents totaling approximately $563 million [S2].
• LivaNova maintains effective disclosure controls and procedures as of September 30, 2026, with ongoing ERP system upgrades impacting internal controls [S2].
• There were no material changes in risk factors as of Q3 2026 compared to the 2025 Form 10-K [S2].
• Recent news highlights include LivaNova surpassing Q3 2026 earnings and revenue expectations and raising full-year 2026 revenue and adjusted diluted EPS guidance [N4][N5].
• The company’s Q3 2026 earnings call and related transcripts provide detailed insights into operational performance and strategic initiatives [N2][N3].
• Healthcare sector stocks including LivaNova showed positive market movement in early November 2026 [N1].